Unfortunately, in the case of many cancers, including breast cancer, inhibitors of the MAP kinase pathway show a short-term effect due to resistance that develops from multiple bypass feedback loops, including activation of the ATK or PI3K/AKT/mTOR pathways (Lee et al. 2019). This evidence concerns the gene MTOR and breast cancer.